Embecta Corp. insider trading
Every open-market purchase and sale by Embecta Corp.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Embecta Corp.’s insiders pay?
From February 15, 2023 to September 8, 2026, 6 insiders reported 12 open-market purchases and 2 sales not made under a pre-set plan in Embecta Corp. Twelve months after each purchase was reported, the shares were −50.3% against the S&P 500 on average (median −49.4%), over 8 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −41.0% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 16, 2023 into $1,719 by November 2, 2026, −38.0% a year. It held shares 93% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,397 (+19.7% a year), and held throughout $19,426 (+19.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Melcher David F | Director | 5 | −50.8% (5) | 0% | 0 | — | May 23, 2025 |
| Elguicze Jacob | SVP and CFO | 2 | −49.4% (1) | 0% | 0 | — | August 13, 2026 |
| Kurdikar Devdatt | President and CEO | 2 | −49.4% (1) | 0% | 0 | — | August 13, 2026 |
| Mann Jeffrey Z | Pres, Pharm Svc&Prod Mgmt, CLO | 2 | −49.4% (1) | 0% | 0 | — | August 13, 2026 |
| Morris Milton Mayo | Director | 0 | — | — | 2 | −41.0% (1) | September 8, 2026 |
| Hombach Robert J. | Director | 1 | — | — | 0 | — | August 13, 2026 |
When several insiders traded Embecta Corp.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Embecta Corp. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −37.4% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 4 buying | not yet | not yet | not yet |
| August 31, 2023 | 3 buying | −1.6% | −37.4% | −30.8% |